StreetInsider.com News Articles

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

AUSTIN, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: With oncology drug-development expenses continuing to rise and regulatory approvals becoming harder to secure, biotechnology companies are placing greater emphasis on extracting more value from existing therapies through cutting-edge delivery technologies rather than betting solely on the discovery of wholly new compounds. Across the life sciences industry, mounting interest is being directed toward nanoparticle-based platforms, intravenous reformulation strategies and precise pharmacokinetic engineering designed to potentially strengthen bioavailability, systemic exposure, tolerability and dosing reliability of established cancer medicines. Within this broader movement, Oncotelic Therapeutics Inc.

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion

Wed, 03 Jun 2026 08:30:00 -0400

Revolution (RVMD) PT Raised to $182 at RBC Capital

Tue, 02 Jun 2026 05:03:52 -0400

RBC Capital analyst Leonid Timashev raised the price target on Revolution (NASDAQ: RVMD) to $182.00 (from $165.00) while maintaining a Outperform rating.

The analyst comments "We believe that RVMD’s daraxonrasib will be able to maintain its leadership in RAS oncology, as investor concerns over the competitive landscape with new pan-RAS inhibitors (chiefly ERAS-0015) are likely overestimating the ability to differentiate from darax. Our structural analysis and in-silico simulations strongly suggest that other drugs are unlikely to be biophysically or pharmacokinetically distinct, setting them a high bar ahead of future data cuts in PDAC and NSCLC, where we expect more mature data

Revolution (RVMD) PT Raised to $182 at RBC Capital

Tue, 02 Jun 2026 05:03:52 -0400

RBC Capital analyst Leonid Timashev raised the price target on Revolution (NASDAQ: RVMD) to $182.00 (from $165.00) while maintaining a Outperform rating.

Revolution Medicines (RVMD) call put ratio 3.3 calls to 1 put after presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO

Tue, 02 Jun 2026 04:19:15 -0400

Revolution Medicines (NASDAQ: RVMD) 30-day option implied volatility is at 58; compared to its 52-week range of 40 to 125. Call put ratio 3.3 calls to 1 put after the company presented the full results from the Phase 3 RASolute 302 trial evaluating daraxonrasib at ASCO.

Revolution (RVMD) PT Raised to $195 at H.C. Wainwright

Mon, 01 Jun 2026 10:45:43 -0400

H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Revolution (NASDAQ: RVMD) to $195.00 (from $169.00) while maintaining a Buy rating.

TD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)

Mon, 01 Jun 2026 08:28:14 -0400

TD Cowen analyst Marc Frahm reiterated a Buy rating on Revolution (NASDAQ: RVMD).

The analyst commented: "Standing Ovation At ASCO For Daraxonrasib's Transformative Efficacy; RASolute302 met its primary OS/PFS endpoints in the G12X subgroup (13.2m/7.3m; HR of 0.4/0.45). As with previously disclosed all comer OS data, this PFS data also compares favorably to 1L chemo (~6m PFS). KOLs expect a broad label and nearly universal use of daraxonrasib in PDAC. RVMD remains a top-pick into PDAC/CRC combo data in H2:26.

The results of the RASolute302 trial were presented today in the ASCO plenary. The additional disclosures, continue to support the prevailing view

Revolution (RVMD) Reiterated at Buy by Stifel

Mon, 01 Jun 2026 07:36:45 -0400

Stifel analyst Laura Prendergast reiterated a Buy rating and $215.00 price target on Revolution (NASDAQ: RVMD).

The analyst commented, "Tonight, during the ASCO Plenary Session, data from RVMD's Ph3 RASolute 302 was presented - slides here & NEJM article here. RVMD held a company webcast following the session.While news of the overwhelming OS benefit daraxonrasib showed in the RASolute 302 ITT (13.2mo versus 6.7mo) was known by the investor community since April's topline, today's ASCO presentation marked a historic moment for the oncology field. The G12X/ITT mPFS of 7.3/7.2mo and ORR of 33%/32% exceeded investor bogey of 7mo mPFS and 30%

Revolution (RVMD) PT Raised to $195 at Oppenheimer

Mon, 01 Jun 2026 07:33:44 -0400

Oppenheimer analyst Jay Olson raised the price target on Revolution (NASDAQ: RVMD) to $195.00 (from $165.00) while maintaining a Outperform rating.

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Revolution Medicines Inc. (NASDAQ: RVMD) announced results from its Phase 3 RASolute 302 clinical trial evaluating daraxonrasib in patients with previously treated metastatic pancreatic ductal adenocarcinoma. The results were presented at the American Society of Clinical Oncology Annual Meeting and published in The New England Journal of Medicine.

The randomized trial enrolled 500 patients who received either once-daily oral daraxonrasib or standard cytotoxic chemotherapy. The study met all primary and key secondary endpoints at the February 10, 2026 data cutoff with a median follow-up of 8.5 months.

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients

Revolution Medicines reports positive pancreatic cancer trial results

Sun, 31 May 2026 08:06:16 -0400

Daraxonrasib demonstrated a 60% reduction in the risk of death compared to chemotherapy. In patients